Novartis AG Profit Margin 2006-2019 | NVS

Current and historical gross margin, operating margin and net profit margin for Novartis AG (NVS) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Novartis AG net profit margin as of December 31, 2019 is 24.73%.
Novartis AG Annual Profit Margins
Novartis AG Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $223.748B $47.498B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $395.123B 17.30
Roche Holding AG (RHHBY) Switzerland $297.156B 0.00
Merck (MRK) United States $210.426B 15.93
Pfizer (PFE) United States $202.051B 12.38
Novo Nordisk (NVO) Denmark $150.250B 25.79
AbbVie (ABBV) United States $139.083B 10.52
Eli Lilly (LLY) United States $135.494B 23.36
AstraZeneca (AZN) United Kingdom $125.547B 27.03
Sanofi (SNY) France $125.032B 14.86
GlaxoSmithKline (GSK) United Kingdom $109.143B 13.84
Bristol-Myers Squibb (BMY) United States $108.152B 14.21
Bayer (BAYRY) Germany $78.409B 11.61
H Lundbeck (HLUYY) Denmark $7.617B 13.23